Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia
NCT03376438
Recruiting
The FAST Trial Registry is a prospective observational cohort study of fetuses with a new diagnosis of atrial flutter (AF) or supraventricular tachycardia (SVT) that is severe enough to consider prenatal treatment (see eligibility criteria below). Aims of the Registry include to establish a large clinical database to determine and compare the efficacy and safety of different prenatal treatment strategies including observation without immediate treatment, transplacental antiarrhythmic fetal treat... Read More
Gender:
Female
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Register for Updates
Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259
Recruiting
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic MYBPC3 mutation-associated nonobstructive hypertrophic cardiomyopathy (nHCM).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/20/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Register for Updates
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NCT05595460
Recruiting
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Utah Huntsman Cancer Hospital, Salt Lake City, Utah
Conditions: SCLC,Extensive Stage
Register for Updates
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05499130
Recruiting
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and endoscopic response (CD) at week 14. Secondary objectives: To evaluate the efficacy and dose response of the 2 different dose regimens as assessed by multiple standard measures To evaluate the safety and tolerability of the 2 different dose regimens To evaluate the immunogenici... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2024
Locations: Teva Investigational Site 15364, Salt Lake City, Utah
Conditions: Crohn Disease, Colitis, Ulcerative
Register for Updates
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants
NCT05412030
Recruiting
This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different dose levels of AFX3772 compared with PCV13. Infants approximately 2 months of age will be enrolled and receive 4 doses of study vaccine over 8 protocol-defined visits spanning a duration of approximately 18 to 21 months. Part 1 is the dose escalation, lead-in portion of t... Read More
Gender:
All
Ages:
Between 42 days and 90 days
Trial Updated:
05/20/2024
Locations: GSK Investigational Site, Layton, Utah
Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal, Pneumonia, Bacterial
Register for Updates
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
NCT05128071
Recruiting
The PRevention Of Methamphetamine Use among Postpartum Women Trial (PROMPT) is randomized controlled trial of postpartum individuals with methamphetamine use disorder to 12 weeks of 200 mg oral micronized progesterone twice daily or placebo. The aims of this study are to assess the feasibility, safety and preliminary efficacy of micronized progesterone for the prevention of return to methamphetamine use. A secondary aim is to assess participant's salivary levels of allopregnanolone with methamph... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Methamphetamine-dependence, Postpartum Abstinence
Register for Updates
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
NCT03482479
Recruiting
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse se... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
All
Ages:
All
Trial Updated:
05/20/2024
Locations: University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Neoplasms
Register for Updates
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
NCT05786924
Recruiting
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanom... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: Huntsman Cancer Institute (University of Utah), Salt Lake City, Utah
Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C
Register for Updates
Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer
NCT05958316
Recruiting
Determine the effects of the Computerized Symptom Assessment Tool (C-SCAT) versus usual care on the primary outcomes of self-efficacy for symptom management and symptom self-management behaviors
Gender:
All
Ages:
Between 15 years and 29 years
Trial Updated:
05/17/2024
Locations: University of Utah Primary Children's Hospital, Salt Lake City, Utah
Conditions: Symptoms and Signs, Cancer, Childhood Cancer
Register for Updates